Korean J Crit Care Med.
1998 Nov;13(2):254-260.
Successful Coronary Interventions with the Aid of Abciximab (ReoPro (R)) in High-Risk Patients: Report of Two Cases
- Affiliations
-
- 1Department of Internal Medicine, Chonnam University Medical School, Kwangju, Korea.
- 2The Research Institute of Medical Sciences, Chonnam National University, Kwangju, Korea.
Abstract
- Abrupt closure of coronary artery during coronary intervention is one of major limitations especially in high-risk patients. Platelets are responsible for composing acute thrombotic occlusion at the site of therapeutic arterial injury. Abciximab (platelet glycoprotein IIb/IIIa receptor blocker) might be helpful in preventing the acute thrombotic occlusion. We experienced an excellent effects of the drug in two cases of high-risk patients, unsuccessful thrombolytics and PTCA with acute occlusion. With additional use of abciximab we overcame the complications and succeeded in getting normal coronary flow and resultant successful angioplasties.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Abciximab (ReoPro)-Induced Thrombocytopenia Diagnosed Through Measurement of Heparin-Dependent Antibody
- Long-term clinical benefit of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab; ReoPro(R)) in diabetic patients undergoing high-risk percutaneous coronary intervention
- Long-Term Clinical Benefits of a Platelet Glycoprotein IIb/IIIa Receptor Blocker, Abciximab (ReoPro (R) ), in High-Risk Diabetic Patients undergoing Percutaneous Coronary Intervention
- A Case of Successful Primary Coronary Intervention for the Total Occlusion of Left Main Stem with the Aid of Abciximab
- Predictive factors for long-term survival after a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab; ReoPro(R)) in patients undergoing high-risk percutaneous coronary intervention in acute myocardial infarction
